Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2004

View Archived Issues

Antihypertensive effects of tachykinin NK3 receptor antagonists

New natural oil stent-coating shows excellent biocompatibility to vascular tissue

ChemoCentryx presents new CCR1 antagonists for inflammatory and immune disorders

Merck presents novel KSP inhibitors with utility in cancer therapy

Merck scientists describe new Edg1 inhibitors and their use as immunosuppressants

Novel 5-HT1A receptors agonists in early development at Pierre Fabre

Novel carboxypeptidase U inhibitors identified by AstraZeneca researchers

AstraZeneca patent covers novel IBAT inhibitors

Aventis scientists design NHE-1 inhibitors for arrhythmia, heart failure, etc.

Pfizer team presents novel GnRH antagonists in a recent patent

Year-end 2003 at Crucell marked by transition to product-focused company

Ilex Oncology reports 2003 developments and provides 2004 outlook

Preliminary data on the efficacy and safety of Emisphere oral insulin in type 2 diabetes

Lower risk for vertebral fractures found with strontium ranelate in postmenopausal women

A pilot study reports improvements with 1-octanol in essential tremor

Assessment of potential cognitive benefits of rofecoxib in Alzheimer's disease

Photodynamic therapy in combination with DMXAA shows promising therapeutic advantages

Tsumura discontinues development of MPEC

Sankyo receives manufacturing approval for Olmetec tablets

Avanir and VaxGen form anthrax antibody alliance

IND filing for new HIV vaccine

Fabrazyme approved in Japan

Department of Defense award for vaccine technology development at Generex

Phase III Ampligen trial completed

Vical secures rights to West Nile virus vaccine

Probactrix well tolerated and safe in safety study

Enrollment completed in phase II Mycograb study

Xencor reports structure of BAFF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...